Progesterone activates GPR126 to promote breast cancer development via the Gi pathway | Zendy

WenTao An | Zendy; Hui Lin | Zendy; Lijuan Ma | Zendy; Chao Zhang | Zendy; Yuan Zheng | Zendy; Qiuxia Cheng | Zendy; Chuanshun Ma | Zendy; Xiang Wu | Zendy; Zihao Zhang | Zendy; Ya-Ni Zhong | Zendy; Menghui Wang | Zendy; Dongfang He | Zendy; Zhao Yang | Zendy; Lutao Du | Zendy; Shiqing Feng | Zendy; Chuanxin Wang | Zendy; Fan Yang | Zendy; Peng Xiao | Zendy; Pengju Zhang | Zendy; Xiao Yu | Zendy; JinPeng Sun | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Progesterone activates GPR126 to promote breast cancer development via the Gi pathway

Author(s) -

WenTao An,

Hui Lin,

Lijuan Ma,

Chao Zhang,

Yuan Zheng,

Qiuxia Cheng,

Chuanshun Ma,

Xiang Wu,

Zihao Zhang,

Ya-Ni Zhong,

Menghui Wang,

Dongfang He,

Zhao Yang,

Lutao Du,

Shiqing Feng,

Chuanxin Wang,

Fan Yang,

Peng Xiao,

Pengju Zhang,

Xiao Yu,

JinPeng Sun

Publication year - 2022

Publication title -

proceedings of the national academy of sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.011

H-Index - 771

eISSN - 1091-6490

pISSN - 0027-8424

DOI - 10.1073/pnas.2117004119

Subject(s) - mutagenesis , carcinogenesis , in vivo , receptor , hormone , chemistry , cancer research , progesterone receptor , steroid , transmembrane protein , microbiology and biotechnology , breast cancer , biochemistry , biology , cancer , medicine , mutation , gene , genetics , estrogen receptor

Significance The steroid hormone progesterone is highly involved in different physiological–pathophysiological processes, including bone formation and cancer progression. Understanding the working mechanisms, especially identifying the receptors of progesterone hormones, is of great value. In the present study, we identified GPR126 as a membrane receptor for both progesterone and 17-hydroxyprogesterone and triggered its downstream G protein signaling. We further characterized the residues of GPR126 that interact with these two ligands and found that progesterone promoted the progression of a triple-negative breast cancer model through GPR126-dependent Gi-SRC signaling. Therefore, developing antagonists targeting GPR126-Gi may provide an alternative therapeutic option for patients with triple-negative breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research